Inovio Pharmaceuticals 2024年第四季度业绩:GAAP每股收益为$-0.65,高于预期的$-0.90,销售额为$117,000K,高于预期的$30,000K

财报速递
19 Mar
Inovio Pharmaceuticals 2024年第四季度的业绩报告显示,其GAAP每股收益为$-0.65,超出市场预期的$-0.90。同时,公司的销售额达到了$117,000K,远远高于预期的$30,000K。

以上内容来自Benzinga Earnings专栏,原文如下:

Inovio Pharmaceuticals Q4 2024 GAAP EPS $(0.65) Beats $(0.90) Estimate, Sales $117.000K Beat $30.000K Estimate

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10